{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:57:18Z","timestamp":1793476638439,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstracts<\/jats:title><jats:p>Imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but the primary and acquired imatinib resistance remains the big hurdle. Molecular mechanisms for CML resistance to tyrosine kinase inhibitors, beyond point mutations in BCR-ABL kinase domain, still need to be addressed. Here, we demonstrated that thioredoxin-interacting protein (TXNIP) is a novel BCR-ABL target gene. Suppression of TXNIP was responsible for BCR-ABL triggered glucose metabolic reprogramming and mitochondrial homeostasis. Mechanistically, Miz-1\/P300 complex transactivates TXNIP through the recognition of TXNIP core promoter region, responding to the c-Myc suppression by either imatinib or BCR-ABL knockdown. TXNIP restoration sensitizes CML cells to imatinib treatment and compromises imatinib resistant CML cell survival, predominantly through the blockage of both glycolysis and glucose oxidation which results in the mitochondrial dysfunction and ATP production. In particular, TXNIP suppresses expressions of the key glycolytic enzyme, hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA), potentially through Fbw7-dependent c-Myc degradation. In accordance, BCR-ABL suppression of TXNIP provided a novel survival pathway for the transformation of mouse bone marrow cells. Knockout of TXNIP accelerated BCR-ABL transformation, whereas TXNIP overexpression suppressed this transformation. Combination of drug inducing TXNIP expression with imatinib synergistically kills CML cells from patients and further extends the survival of CML mice. Thus, the activation of TXNIP represents an effective strategy for CML treatment to overcome resistance.<\/jats:p>","DOI":"10.1038\/s41419-023-05811-2","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:04:24Z","timestamp":1682330664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP"],"prefix":"10.1038","volume":"14","author":[{"given":"Lin","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3272-2385","authenticated-orcid":false,"given":"Liangliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"5811_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2010.143","volume":"24","author":"Y Chen","year":"2010","unstructured":"Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010;24:1545\u201354.","journal-title":"Leukemia"},{"key":"5811_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441\u201353.","journal-title":"Nat Rev Cancer"},{"key":"5811_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1124\/pr.55.3.4","volume":"55","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharm Rev. 2003;55:401\u201323.","journal-title":"Pharm Rev"},{"key":"5811_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876\u201380.","journal-title":"Science"},{"key":"5811_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2006;16:92\u20139.","journal-title":"Curr Opin Genet Dev"},{"key":"5811_CR6","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1172\/JCI31988","volume":"117","author":"DW Sherbenou","year":"2007","unstructured":"Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007;117:2067\u201374.","journal-title":"J Clin Invest"},{"key":"5811_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.leu.2404137","volume":"20","author":"JS Khorashad","year":"2006","unstructured":"Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658\u201363.","journal-title":"Leukemia"},{"key":"5811_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7:345\u201356.","journal-title":"Nat Rev Cancer"},{"key":"5811_CR9","doi-asserted-by":"publisher","first-page":"8066","DOI":"10.1158\/0008-5472.CAN-10-0608","volume":"70","author":"EF Mason","year":"2010","unstructured":"Mason EF, Zhao Y, Goraksha-Hicks P, Coloff JL, Gannon H, Jones SN, et al. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res. 2010;70:8066\u201376.","journal-title":"Cancer Res"},{"key":"5811_CR10","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","volume":"10","author":"S Gottschalk","year":"2004","unstructured":"Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res. 2004;10:6661\u20138.","journal-title":"Clin Cancer Res"},{"key":"5811_CR11","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","volume":"24","author":"K Barnes","year":"2005","unstructured":"Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005;24:3257\u201367.","journal-title":"Oncogene"},{"key":"5811_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","volume":"158","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, et al. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharm. 2009;158:588\u2013600.","journal-title":"Br J Pharm"},{"key":"5811_CR13","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","volume":"15","author":"DJ Kominsky","year":"2009","unstructured":"Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009;15:3442\u201350.","journal-title":"Clin Cancer Res"},{"key":"5811_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017;23:1234\u201340.","journal-title":"Nat Med"},{"key":"5811_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cmet.2007.05.011","volume":"5","author":"DM Muoio","year":"2007","unstructured":"Muoio DM. TXNIP links redox circuitry to glucose control. Cell Metab. 2007;5:412\u20134.","journal-title":"Cell Metab"},{"key":"5811_CR16","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1073\/pnas.0712199105","volume":"105","author":"CA Stoltzman","year":"2008","unstructured":"Stoltzman CA, Peterson CW, Breen KT, Muoio DM, Billin AN, Ayer DE. Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci USA. 2008;105:6912\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5811_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/1947601910389604","volume":"1","author":"MG Elgort","year":"2010","unstructured":"Elgort MG, O\u2019Shea JM, Jiang Y, Ayer DE. Transcriptional and translational downregulation of thioredoxin interacting protein is required for metabolic reprogramming during G(1). Genes Cancer. 2010;1:893\u2013907.","journal-title":"Genes Cancer"},{"key":"5811_CR18","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1073\/pnas.1501555112","volume":"112","author":"L Shen","year":"2015","unstructured":"Shen L, O\u2019Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA. 2015;112:5425\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5811_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cell.2018.08.017","volume":"175","author":"WJ Sullivan","year":"2018","unstructured":"Sullivan WJ, Mullen PJ, Schmid EW, Flores A, Momcilovic M, Sharpley MS, et al. Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization. Cell 2018;175:117\u201332.e21.","journal-title":"Cell"},{"key":"5811_CR20","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1158\/1078-0432.CCR-15-2380","volume":"22","author":"S Ji","year":"2016","unstructured":"Ji S, Qin Y, Liang C, Huang R, Shi S, Liu J, et al. FBW7 (F-box and WD repeat domain-containing 7) negatively regulates glucose metabolism by targeting the c-Myc\/TXNIP (thioredoxin-binding protein) axis in pancreatic cancer. Clin Cancer Res. 2016;22:3950\u201360.","journal-title":"Clin Cancer Res"},{"key":"5811_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2018.08.069","volume":"504","author":"X Qu","year":"2018","unstructured":"Qu X, Sun J, Zhang Y, Li J, Hu J, Li K, et al. c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer. Biochem Biophys Res Commun. 2018;504:415\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"5811_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.molcel.2013.01.035","volume":"49","author":"N Wu","year":"2013","unstructured":"Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49:1167\u201375.","journal-title":"Mol Cell"},{"key":"5811_CR23","doi-asserted-by":"publisher","first-page":"38027","DOI":"10.1074\/jbc.M111.275503","volume":"286","author":"CA Stoltzman","year":"2011","unstructured":"Stoltzman CA, Kaadige MR, Peterson CW, Ayer DE. MondoA senses non-glucose sugars: regulation of thioredoxin-interacting protein (TXNIP) and the hexose transport curb. J Biol Chem. 2011;286:38027\u201334.","journal-title":"J Biol Chem"},{"key":"5811_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/35070076","volume":"3","author":"P Staller","year":"2001","unstructured":"Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3:392\u20139.","journal-title":"Nat Cell Biol"},{"key":"5811_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ni1245","volume":"6","author":"RT Phan","year":"2005","unstructured":"Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6:1054\u201360.","journal-title":"Nat Immunol"},{"key":"5811_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-4939-3661-8_13","volume":"1438","author":"C Peng","year":"2016","unstructured":"Peng C, Li S. Chronic myeloid leukemia (CML) mouse model in translational research. Methods Mol Biol. 2016;1438:225\u201343.","journal-title":"Methods Mol Biol"},{"key":"5811_CR27","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","volume":"101","author":"M Welcker","year":"2004","unstructured":"Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101:9085\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5811_CR28","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1158\/0008-5472.CAN-11-3605","volume":"72","author":"WB Tsai","year":"2012","unstructured":"Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, et al. Activation of Ras\/PI3K\/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012;72:2622\u201333.","journal-title":"Cancer Res"},{"key":"5811_CR29","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1128\/MCB.24.13.5923-5936.2004","volume":"24","author":"JW Kim","year":"2004","unstructured":"Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O\u2019Donnell KA, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol. 2004;24:5923\u201336.","journal-title":"Mol Cell Biol"},{"key":"5811_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18:930\u20137.","journal-title":"Clin Cancer Res"},{"key":"5811_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1460-9592.2005.01548.x","volume":"15","author":"SL Barcelona","year":"2005","unstructured":"Barcelona SL, Thompson AA, Cote CJ. Intraoperative pediatric blood transfusion therapy: a review of common issues. Part I: hematologic and physiologic differences from adults; metabolic and infectious risks. Paediatr Anaesth. 2005;15:716\u201326.","journal-title":"Paediatr Anaesth"},{"key":"5811_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O\u2019Hare","year":"2011","unstructured":"O\u2019Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17:212\u201321.","journal-title":"Clin Cancer Res"},{"key":"5811_CR33","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18:5546\u201353.","journal-title":"Clin Cancer Res"},{"key":"5811_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Disco. 2015;5:1024\u201339.","journal-title":"Cancer Disco"},{"key":"5811_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrc2817","volume":"10","author":"DA Tennant","year":"2010","unstructured":"Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267\u201377.","journal-title":"Nat Rev Cancer"},{"key":"5811_CR36","doi-asserted-by":"publisher","first-page":"e21924","DOI":"10.1371\/journal.pone.0021924","volume":"6","author":"J Kluza","year":"2011","unstructured":"Kluza J, Jendoubi M, Ballot C, Dammak A, Jonneaux A, Idziorek T, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS ONE. 2011;6:e21924.","journal-title":"PLoS ONE"},{"key":"5811_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.leukres.2016.08.006","volume":"49","author":"E Berman","year":"2016","unstructured":"Berman E, Jhanwar S, Hedvat C, Arcila ME, Wahab OA, Levine R, et al. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). Leuk Res. 2016;49:108\u201312.","journal-title":"Leuk Res"},{"key":"5811_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7\u201322.","journal-title":"Leukemia"},{"key":"5811_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17839-5","volume":"11","author":"ME Bechard","year":"2020","unstructured":"Bechard ME, Smalling R, Hayashi A, Zhong Y, Word AE, Campbell SL, et al. Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis. Nat Commun. 2020;11:4055.","journal-title":"Nat Commun"},{"key":"5811_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1053\/j.gastro.2021.04.041","volume":"161","author":"Y Lu","year":"2021","unstructured":"Lu Y, Li Y, Liu Q, Tian N, Du P, Zhu F, et al. MondoA\u2013thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment. Gastroenterology 2021;161:575\u201391.e16.","journal-title":"Gastroenterology"},{"key":"5811_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01269-4","volume":"19","author":"S Shen","year":"2020","unstructured":"Shen S, Yao T, Xu Y, Zhang D, Fan S, Ma J. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 2020;19:151.","journal-title":"Mol Cancer"},{"key":"5811_CR42","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1073\/pnas.0800293105","volume":"105","author":"ST Hui","year":"2008","unstructured":"Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, et al. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA. 2008;105:3921\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5811_CR43","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jhep.2010.09.025","volume":"54","author":"HJ Kwon","year":"2011","unstructured":"Kwon HJ, Won YS, Yoon YD, Yoon WK, Nam KH, Choi IP, et al. Vitamin D3 up-regulated protein 1 deficiency accelerates liver regeneration after partial hepatectomy in mice. J Hepatol. 2011;54:1168\u201376.","journal-title":"J Hepatol"},{"key":"5811_CR44","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1038\/s41388-018-0408-8","volume":"37","author":"B Zhang","year":"2018","unstructured":"Zhang B, Lyu J, Liu Y, Wu C, Yang EJ, Pardeshi L, et al. BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition. Oncogene 2018;37:6341\u201356.","journal-title":"Oncogene"},{"key":"5811_CR45","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-18-3776","volume":"25","author":"S Kregel","year":"2019","unstructured":"Kregel S, Malik R, Asangani IA, Wilder-Romans K, Rajendiran T, Xiao L, et al. Functional and mechanistic interrogation of BET bromodomain degraders for the treatment of metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:4038\u201348.","journal-title":"Clin Cancer Res"},{"key":"5811_CR46","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/ajh.26650","volume":"97","author":"B Peter","year":"2022","unstructured":"Peter B, Eisenwort G, Sadovnik I, Bauer K, Willmann M, Rulicke T, et al. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia. Am J Hematol. 2022;97:1215\u201325.","journal-title":"Am J Hematol"},{"key":"5811_CR47","doi-asserted-by":"publisher","first-page":"9409","DOI":"10.3892\/mmr.2017.7835","volume":"16","author":"Y Dong","year":"2017","unstructured":"Dong Y, Gao X, Zhao Y, Wei M, Xu L, Yang G, et al. Semirandom mutagenesis profile of BCRABL during imatinib resistance acquirement in K562 cells. Mol Med Rep. 2017;16:9409\u201314.","journal-title":"Mol Med Rep"},{"key":"5811_CR48","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","volume":"119","author":"H Yuan","year":"2012","unstructured":"Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012;119:1904\u201314.","journal-title":"Blood"},{"key":"5811_CR49","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41388-017-0118-7","volume":"37","author":"L Shen","year":"2018","unstructured":"Shen L, Qu X, Li H, Xu C, Wei M, Wang Q, et al. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21\/p27 axis. Oncogene 2018;37:1759\u201374.","journal-title":"Oncogene"},{"key":"5811_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.48","volume":"3","author":"L Shen","year":"2014","unstructured":"Shen L, Qu X, Ma Y, Zheng J, Chu D, Liu B, et al. Tumor suppressor NDRG2 tips the balance of oncogenic TGF-beta via EMT inhibition in colorectal cancer. Oncogenesis 2014;3:e86.","journal-title":"Oncogenesis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05811-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:09:32Z","timestamp":1682334572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05811-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}